Shuttle Pharma Files S-1 for Future Securities Offering
Ticker: SHPH · Form: S-1 · Filed: Aug 5, 2025 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | S-1 |
| Filed Date | Aug 5, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: S-1 Filing, Pharmaceuticals, Emerging Growth Company, Capital Raise, Dilution Risk, Biotech, SEC Filing
TL;DR
**Shuttle Pharma's S-1 is a red flag for dilution, signaling a cash grab for a speculative pharma play.**
AI Summary
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed an S-1 registration statement on August 5, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a potential capital raise. The company, classified as a non-accelerated filer, smaller reporting company, and emerging growth company, operates in the pharmaceutical preparations industry (SIC 2834). Christopher Cooper serves as the Interim Chief Executive Officer, with the principal executive offices located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879. The filing does not disclose specific revenue or net income figures, nor does it detail key business changes or strategic outlook, focusing instead on the mechanics of a future offering. Key risks are implicitly tied to its status as an emerging growth company and the inherent uncertainties of drug development in the pharmaceutical sector. The company's fiscal year ends on December 31.
Why It Matters
This S-1 filing signals Shuttle Pharmaceuticals' intent to raise capital, which is crucial for funding its drug development pipeline in the highly competitive pharmaceutical industry. For investors, it means potential dilution from new share issuance, but also a chance to invest in an emerging growth company focused on pharmaceutical preparations. Employees and customers will be impacted by the company's ability to secure funding, which directly affects research, development, and ultimately, product availability. The broader market will watch how SHPH navigates capital markets, especially as a smaller reporting company in a sector dominated by larger players.
Risk Assessment
Risk Level: high — The risk level is high because Shuttle Pharmaceuticals is an 'emerging growth company' and a 'smaller reporting company,' indicating limited operating history and resources. The filing is for a 'delayed or continuous basis' offering, which suggests ongoing capital needs without specifying the use of proceeds or current financial health, increasing uncertainty for investors.
Analyst Insight
Investors should exercise extreme caution and await further details on the offering's terms, including pricing and the specific use of proceeds. Given the 'high' risk level and 'bearish' sentiment, consider this a speculative investment and conduct thorough due diligence on their drug pipeline and financial statements once available.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Christopher Cooper | Interim Chief Executive Officer |
Key Numbers
- 2025-08-05 — Filing Date (Date S-1 was filed with the SEC)
- 333-289231 — SEC File Number (Unique identifier for this registration statement)
- 2834 — SIC Code (Primary Standard Industrial Classification for Pharmaceutical Preparations)
- 1231 — Fiscal Year End (Shuttle Pharmaceuticals' fiscal year ends on December 31)
- 401 Professional Drive, Suite 260 — Business Address (Principal executive offices of Shuttle Pharmaceuticals)
- (240) 430-4212 — Business Phone (Contact number for Shuttle Pharmaceuticals)
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant filing S-1
- Christopher Cooper (person) — Interim Chief Executive Officer
- Sichenzia Ross Ference Carmel LLP (company) — Legal counsel for the registrant
- Ross Carmel (person) — Attorney at Sichenzia Ross Ference Carmel LLP
- Jeff Cahlon (person) — Attorney at Sichenzia Ross Ference Carmel LLP
- SEC (regulator) — Securities and Exchange Commission
- Delaware (regulator) — State of incorporation
- Rule 415 (regulator) — SEC rule for delayed or continuous offerings
- Rule 12b-2 (regulator) — SEC rule defining filer statuses
- Section 7(a)(2)(B) (regulator) — Securities Act section for accounting standards
FAQ
What is the purpose of Shuttle Pharmaceuticals Holdings, Inc.'s S-1 filing?
The S-1 filing by Shuttle Pharmaceuticals Holdings, Inc. on August 5, 2025, is a registration statement for a delayed or continuous offering of securities pursuant to Rule 415 under the Securities Act of 1933, indicating their intent to raise capital in the future.
Who is the Interim Chief Executive Officer of Shuttle Pharmaceuticals?
Christopher Cooper is listed as the Interim Chief Executive Officer of Shuttle Pharmaceuticals Holdings, Inc., with their principal executive offices located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
What is Shuttle Pharmaceuticals' industry classification?
Shuttle Pharmaceuticals Holdings, Inc. is classified under the Primary Standard Industrial Classification Code Number 2834, which corresponds to 'Pharmaceutical Preparations'.
Is Shuttle Pharmaceuticals considered an emerging growth company?
Yes, Shuttle Pharmaceuticals Holdings, Inc. has indicated by check mark that it is an 'emerging growth company,' a 'smaller reporting company,' and a 'non-accelerated filer' according to the definitions in Rule 12b-2 of the Exchange Act.
What are the potential implications for investors from SHPH's S-1 filing?
For investors, the S-1 filing implies potential future dilution as Shuttle Pharmaceuticals intends to offer new securities. This capital raise is crucial for funding its operations and drug development, but specific terms and financial details are not yet disclosed.
Where are Shuttle Pharmaceuticals' principal executive offices located?
Shuttle Pharmaceuticals Holdings, Inc.'s principal executive offices are located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879, with a business phone number of (240) 430-4212.
When does Shuttle Pharmaceuticals' fiscal year end?
Shuttle Pharmaceuticals Holdings, Inc.'s fiscal year ends on December 31, as indicated by the 'FISCAL YEAR END: 1231' in the filing data.
What legal firm is representing Shuttle Pharmaceuticals in this S-1 filing?
Sichenzia Ross Ference Carmel LLP, with attorneys Ross Carmel, Esq. and Jeff Cahlon, Esq., is representing Shuttle Pharmaceuticals Holdings, Inc. for this S-1 registration statement.
What is the SEC file number for Shuttle Pharmaceuticals' S-1?
The SEC file number for Shuttle Pharmaceuticals Holdings, Inc.'s S-1 registration statement is 333-289231, filed on August 5, 2025.
What are the primary risks associated with investing in Shuttle Pharmaceuticals based on this S-1?
The primary risks, while not explicitly detailed in this S-1, are inherent in Shuttle Pharmaceuticals' status as an 'emerging growth company' and 'smaller reporting company,' implying a less established operational history, potential for significant capital needs, and the high-risk nature of pharmaceutical development.
Risk Factors
- Delayed or Continuous Offering [medium — financial]: The company is filing an S-1 for a delayed or continuous offering under Rule 415. This indicates a potential need for capital and suggests that the company may not have sufficient current funding or may be planning for future funding needs without a defined immediate use.
- Emerging Growth Company Status [medium — operational]: As an emerging growth company, SHPH is subject to specific regulatory considerations and may face heightened scrutiny regarding its disclosures and compliance. This status also allows for extended transition periods for new accounting standards, which could impact future financial reporting comparability.
- Pharmaceutical Industry Uncertainties [high — market]: Operating in the pharmaceutical preparations industry (SIC 2834) inherently involves significant risks related to drug development, clinical trials, regulatory approvals, and market acceptance. The success of the company is heavily dependent on the efficacy and safety of its pipeline products.
Industry Context
Shuttle Pharmaceuticals Holdings operates within the highly competitive pharmaceutical preparations industry (SIC 2834). This sector is characterized by extensive research and development, lengthy and costly clinical trials, and stringent regulatory approval processes. Key trends include the increasing demand for novel therapeutics, advancements in biotechnology, and evolving healthcare policies.
Regulatory Implications
As an emerging growth company and a non-accelerated filer, SHPH is subject to specific SEC disclosure requirements. The S-1 filing itself is a critical regulatory step for any public offering. The company must navigate the complex regulatory landscape of drug development and approval, including potential FDA oversight.
What Investors Should Do
- Review full S-1 filing for detailed business and risk disclosures.
- Monitor future SEC filings for updates on offering details and financial performance.
- Assess the company's cash burn rate and funding runway once financial details become available.
Key Dates
- 2025-08-05: S-1 Filing Date — Indicates the company's intention to offer securities to the public, signaling a potential capital raise and increased regulatory oversight.
- 2025-08-04: Filing as of Date — The date as of which the information in the filing is considered current, providing a snapshot of the company's status.
Glossary
- S-1 Registration Statement
- The initial document filed with the SEC by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and management. (This is the primary document filed by SHPH, outlining their intent to raise capital and providing foundational information for potential investors.)
- Rule 415
- A regulation that permits companies to register securities for a delayed or continuous offering, allowing flexibility in timing and pricing of future sales. (SHPH is utilizing Rule 415, indicating they are planning for future capital needs without a fixed immediate offering date.)
- Emerging Growth Company
- A designation for companies with less than $1.235 billion in annual gross revenue that are eligible for certain exemptions from SEC reporting requirements. (SHPH qualifies as an EGC, which impacts its disclosure obligations and allows for extended transition periods for new accounting standards.)
- SIC Code 2834
- Standard Industrial Classification code for Pharmaceutical Preparations, covering establishments primarily engaged in manufacturing medicinal and botanical drugs and preparation. (This code categorizes SHPH within the pharmaceutical industry, highlighting its core business operations and competitive landscape.)
Year-Over-Year Comparison
This is the initial S-1 filing for Shuttle Pharmaceuticals Holdings, Inc., as indicated by the filing date of August 5, 2025. Therefore, a comparison of key metrics, revenue growth, margin changes, or new risks against a previous filing is not possible at this time. The filing establishes the company's current status as a non-accelerated filer, smaller reporting company, and emerging growth company, setting the baseline for future disclosures.
Filing Details
This Form S-1 (Form S-1) was filed with the SEC on August 5, 2025 by Christopher Cooper regarding Shuttle Pharmaceuticals Holdings, Inc. (SHPH).